TABLE 4.

Incremental cancer-attributable per-year OOP expenditures for female cancer survivors compared with male cancer survivors

	Current cancer condition		No current cancer condition
Cancer status and type	Incremental cancer-attributable average out-of-pocket expenditure, $USa	P b	Incremental cancer-attributable average out-of-pocket expenditure, $USa	P b
Lung cancer	316	0.236	−428	0.264
Colon cancer	−108	0.638	−60	0.765
Melanoma	77	0.693	−191	0.263
Non–Hodgkin lymphoma	−229	0.368	334	0.271
Nonmelanoma/other skin cancer	97	0.364	−208	0.044
Bladder cancer	−541	0.119	−542	0.180
Other/unspecified	−866	<0.001	−210	0.061
≥ Two cancers	−564	0.021	−91	0.669

^aCancer-attributable incremental per year OOP expenditure values were obtained by deducting cancer attributable OOP expenditure values for males from the respective values for females for each cancer type. Negative sing means that the cancer-attributable OOP expenditure for females was lower than for males.

^b P value represents the statistical significance obtained using 1,000 permutated replicates to test the hypothesis that for each specific cancer type the cancer attributable average OOP expenditures for female survivors are different from those of male survivors.